Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1986-4-30
|
pubmed:abstractText |
Incidence and clinical symptomatology of CMV-infection was investigated in 83 patients, who received cadaveric renal transplants in 1982 and 1983. CMV-antibody status was determined using an ELISA-technique, 43 of the 83 patients (52%) were seronegative, and 40 (48%) were seropositive for CMV before transplantation. Seroconversion (i.e. primary CMV-infection) or an increase in titre (i.e. reactivation or reinfection) was found in 18 cases (42% and 45%, respectively) in both groups. 89% of all infections occurred within the first 3 months. Clinical symptomatology was much more severe in the group with primary CMV-infection; all cases with atypical pneumonia (n = 8) and both fatal cases belonged to this group. Preformed CMV-antibodies thus appeared to prevent severe syndromes associated with CMV-infection. Therefore a randomized controlled study was started in 1984 in order to investigate the efficacy of an i.v. applicable CMV-hyperimmunoglobulin passively administered prior to the transplant procedure. The passive immunization was not capable of preventing CMV-infection in every case: 2 (late) seroconversions did occur, but in both cases subclinical infections were diagnosed, whereas in the control group CMV-infections were regularly associated with typical clinical complications (prolonged fever, liver damage, leucopenia etc.). Thus prophylactic CMV-hyperimmunoglobulin seems to be capable of preventing the occurrence of severe CMV-syndromes post transplantation. The study is being continued.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/cytomegalovirus-specific...
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-8886
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
23-8
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:3008313-Antibodies, Viral,
pubmed-meshheading:3008313-Cytomegalovirus Infections,
pubmed-meshheading:3008313-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:3008313-Follow-Up Studies,
pubmed-meshheading:3008313-Humans,
pubmed-meshheading:3008313-Immunization, Passive,
pubmed-meshheading:3008313-Immunoglobulin G,
pubmed-meshheading:3008313-Immunoglobulin M,
pubmed-meshheading:3008313-Immunoglobulins,
pubmed-meshheading:3008313-Immunoglobulins, Intravenous,
pubmed-meshheading:3008313-Kidney Transplantation,
pubmed-meshheading:3008313-Pneumonia, Viral,
pubmed-meshheading:3008313-Prospective Studies
|
pubmed:year |
1985
|
pubmed:articleTitle |
Incidence of cytomegalovirus-infection after renal transplantation and first experiences with prophylactic hyperimmunoglobulin.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|